Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients.

Saved in:
Bibliographic Details
Title: Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients.
Authors: Mima F; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan., Fuji S; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan., Shibata K; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan., Kida S; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan., Tsutsumi K; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan., Tada Y; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan., Shingai Y; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan., Yuda S; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan., Yokota T; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan., Ishikawa J; Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Source: Blood cell therapy [Blood Cell Ther] 2023 Jun 09; Vol. 6 (3), pp. 77-79. Date of Electronic Publication: 2023 Jun 09 (Print Publication: 2023).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Asia-Pacific Blood and Marrow Transplantation Country of Publication: Japan NLM ID: 9918333884906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2432-7026 (Electronic) Linking ISSN: 24327026 NLM ISO Abbreviation: Blood Cell Ther Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2432-7026
DOI:10.31547/bct-2023-003